PACS Group, Inc. is giving Wall Street a reason to smile, with its Salt Lake City roots, NYSE ticker PACS, and a stock that is rallying smartly today while still showing solid gains over the year despite bouts of volatility.
From the Wasatch Front to Wall Street
Salt Lake City is better known for powder snow and tech start‑ups than for post‑acute care roll‑ups, but PACS Group, Inc. is quietly rewriting that script. The post‑acute and skilled‑nursing operator, listed on the New York Stock Exchange under the ticker PACS, has emerged as one of the healthcare sector’s more intriguing growth stories, pairing Mountain West pragmatism with Wall Street ambitions.
The company’s latest first‑quarter report underscored that ambition, as management delivered both stronger revenue and higher earnings than many analysts had penciled into their models. For an industry often described in muted tones—reimbursement schedules and occupancy rates do not typically inspire cocktail‑party chatter—PACS has managed to turn solid execution into something close to market buzz.
Earnings Beat Lights a Fire Under PACS
Investors did not need a second invitation after the company’s Q1 numbers crossed the tape. Revenue climbed at a healthy double‑digit clip versus the prior year, outpacing consensus estimates, while adjusted earnings per share came in comfortably ahead of Wall Street forecasts, signaling that the company is not just growing, but growing efficiently.
Net income surged sharply year‑over‑year, reflecting both higher volumes and disciplined cost control across PACS’s network of post‑acute facilities. Trading volume spiked as the earnings release and guidance update filtered through the market, a sign that portfolio managers were not content to watch this one from the sidelines.
Stock Performance Today: A Post‑Acute Pop
The market reaction has been swift and emphatic. In today’s session, shares of PACS have jumped strongly, trading roughly in the upper‑30s after investors digested the earnings beat and raised full‑year outlook. Intraday, the stock has been changing hands well above its prior close, with gains approaching the high‑teens percentage range as buyers leaned in and short‑term skeptics scrambled to reassess their models.
That move has pushed PACS toward the upper end of its recent trading range, bringing it closer to its 52‑week highs and signaling renewed confidence in the company’s trajectory. For a name that had seen periodic pullbacks in recent months, today’s action looks less like a dead‑cat bounce and more like a market that just received new information and decided it had been a bit too cautious.
Year‑to‑Date: A Choppy but Constructive Climb
Zooming out, PACS’s year‑to‑date path has not been a straight line, but the trend has been constructive. Even after earlier drawdowns that left the stock modestly negative versus the broader S&P 500 at certain points, the recent rally has helped restore much of that lost ground and then some, leaving shares up solidly on a year‑to‑date basis.
Performance tables now show PACS ahead over the one‑month and three‑month horizons, with gains that would look respectable in any market, let alone one where healthcare sentiment has been mixed amid policy debates and margin concerns. The stock’s ability to rebound from earlier weakness suggests that investors are increasingly willing to look through short‑term noise in favor of longer‑term cash‑flow potential in a consolidating skilled‑nursing landscape.
Why PACS Is on Investors’ Radar
Several factors are helping keep PACS in active rotation on Wall Street screens. The company continues to expand its footprint through targeted acquisitions, including recent additions in markets such as Alaska that broaden its geographic reach and reinforce its role as a consolidator in post‑acute care. Management has also refreshed its leadership bench, adding an experienced chief financial officer while maintaining continuity at the board level, which should give investors added comfort as the growth story matures.
With a market capitalization now in the mid‑single‑digit billions and a valuation that reflects both growth prospects and execution risk, PACS has graduated from under‑the‑radar newcomer to serious healthcare contender. For investors, the calculus is straightforward: if Salt Lake City’s post‑acute specialist continues to pair double‑digit revenue growth with disciplined margin management, the stock’s recent move may be less a one‑day snow squall and more the start of a longer‑season uptrend.
BuzzFeed, Inc. just found itself back in the headlines for something other than listicles and layoffs: a proposed majority-stake investment that has turned its stock into one of Wall Street’s more surprising momentum trades of the week.
Byron Allen Logs On: A $120 Million Vote of Confidence
BuzzFeed, Inc. (NASDAQ: BZFD) has entered into a transaction agreement with Allen Family Digital, LLC, an affiliate of Byron Allen’s family office, that would see Allen invest $120 million for a majority stake in the once high-flying digital media pioneer. Under the deal, Allen’s vehicle will purchase 40 million shares at $3.00 apiece, giving it roughly 52% of BuzzFeed’s outstanding shares when the transaction closes.
The funding structure mixes old-school cash with a modern patience test: $20 million paid at closing and a $100 million promissory note due in five years, carrying a 5% annual interest rate. For a company that has spent the last few years trading more in skepticism than sizzle, the commitment amounts to a sizable show of faith that digital media isn’t a relic of the 2010s so much as a turnaround play for those with the appetite—and capital—for volatility.
From Meme Factory to AI Lab
As part of the agreement, Byron Allen will become Chairman and Chief Executive Officer of BuzzFeed, while founder Jonah Peretti will step aside from the top job and move into a newly created role as President of BuzzFeed AI. The title is a not-so-subtle acknowledgment that the company’s future may rely less on quizzes about which sandwich you are and more on AI-driven content tools, personalization, and automation.
Peretti’s shift to an AI-focused portfolio comes after years of financial strain, including warnings earlier this year that the company’s debt load and recurring losses raised questions about its ability to continue as a going concern. Allen’s entrance, then, is not merely a change of name on the door; it’s a recapitalization designed to buy time, invest in product, and attempt to rebuild a business model that has been squeezed by platform algorithms, ad-market shifts, and a sudden market preference for profits over pageviews.
Ticker Talk: BZFD’s Two-Day Awakening
The market’s reaction to the deal has been anything but subtle. BuzzFeed’s stock, trading under the ticker BZFD, has erupted from penny-stock obscurity into the day-trader spotlight. Following the announcement of the proposed majority investment, BZFD shares surged nearly 130% in after-hours trading on Monday as investors digested the prospect of a $120 million lifeline and a high-profile media mogul at the helm.
That momentum carried into the regular session, with BZFD recently soaring about 98.7% to roughly $1.45 on heavy volume, landing on “trending stocks” lists and reminding traders that media turnarounds can move faster than a headline refresh. As of the latest snapshot around the announcement window, the stock has traded as high as roughly $2.27 intraday and recently changed hands near $1.72, still more than double earlier lows and well above the sub-dollar levels that had been signaling investor fatigue. For long-time shareholders, the move feels less like a rally and more like a partial reprieve; for momentum traders, it’s another example of how quickly sentiment can pivot once fresh capital enters the story.
The Allen Playbook: From Paramount Dreams to BuzzFeed Reality
Byron Allen has made no secret of his ambition to build a diversified media empire, previously circling assets from TV networks to Paramount itself. BuzzFeed, with its mix of digital brands, news heritage, and cultural reach, offers a smaller but potentially strategic foothold in an ecosystem where streaming, social media, and digital advertising continue to collide.
Under the proposed deal, Allen gets a controlling stake in a company that still commands significant audience awareness—and one that can be reoriented toward higher-margin areas like branded content, AI-enhanced production, and syndication across his broader media portfolio. For BuzzFeed, the alignment with an established media operator offers more than just cash; it offers distribution, deal-making experience, and a shot at relevance in a market that had largely written the brand off as yesterday’s viral sensation.
What’s Next for Investors Watching BZFD
For investors eyeing BZFD after this sudden rerating, the story now hinges on execution: closing the transaction, deploying the $120 million efficiently, and turning BuzzFeed’s blend of audience data, brand recognition, and AI ambitions into something that resembles a durable business. The recent price action reflects renewed optimism, but it also bakes in a fair amount of expectation that Allen’s stewardship will upgrade BuzzFeed from a cautionary tale to a credible turnaround narrative.
In practical terms, that means investors will be watching for updates on integration, restructuring, and product strategy under the new CEO, as well as any early signs that BuzzFeed AI is more than just a timely title. Until then, BZFD is likely to remain a high-beta, news-driven ticker—one whose fortunes will be written less by nostalgia for viral content and more by whether a seasoned media dealmaker can teach an aging digital native some new, cash-flow-positive tricks.
Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other.
Healthcare Becomes the New Family Office Heirloom
After a cautious March tied to geopolitical jitters around the Iran conflict, family offices snapped back into action in April, logging 55 direct investments versus 39 the prior month, according to Fintrx data shared with CNBC. Nearly one‑third of those checks went into healthcare and life sciences, effectively turning the sector into the new “must‑have” asset class between the art collection and the ski chalet.
The renewed momentum follows a broader pattern: family offices have been steadily growing as a force in private markets, now overseeing trillions in assets and increasingly bypassing traditional funds to back companies directly. Surveys show healthcare innovation ranks just behind artificial intelligence as a top thematic focus, with 50% of family offices flagging it as a priority, compared with 65% for AI. For wealthy families, the future, it seems, is part chips, part clinical trials.
From Waiting Room To Deal Room
If these healthcare bets feel personal, that’s because they often are. CNBC notes that many family offices cite direct experiences – from navigating complex diagnoses to losing loved ones – as catalysts for their investment theses in therapeutics, diagnostics, and digital health. Dolby Family Ventures, for instance, joined a €53 million Series B round for Exciva, an Alzheimer’s agitation treatment company, a cause linked to the late Ray Dolby’s own battle with the disease.
This mix of lived experience and long‑dated capital is giving rise to a distinct investor type: part venture capitalist, part legacy architect. Unlike traditional PE funds marching to a 10‑year clock, family offices can underwrite therapies and platforms whose payoff looks more like a medical timeline than a quarterly earnings call. In the process, they are turning the family narrative – once written in real estate and public stocks – into one that also runs through biotech labs and AI‑enabled clinics.
The April Deals: AI Doctors And Cancer Codebreakers
April’s return to form wasn’t just about deal volume; it was about where the money flowed. Emerson Collective, Laurene Powell Jobs’ investment and philanthropy platform, backed two of the month’s headline healthcare transactions: Ultralight and Stipple Bio. Ultralight, an AI‑driven software platform for personalized healthcare solutions, raised about $9.3 million, effectively positioning itself as a digital co‑pilot for clinicians navigating increasingly complex patient data.
On the therapeutics side, Stipple Bio secured a $100 million Series A, co‑led by Andreessen Horowitz, to advance targeted cancer treatments. The round underscored how quickly family offices have moved from watching oncology breakthroughs on conference stages to helping write the cap tables behind them. Together, these deals illustrate the barbell strategy taking hold in healthcare: software platforms that make the system smarter on one end, and precision therapies that may redefine standards of care on the other.
Enter Naya Therapeutics: Astatine, Alpha And Boardroom Signal
Into this backdrop steps Naya Therapeutics, a clinical‑stage company building a portfolio around astatine‑211–based alpha therapeutics for hard‑to‑treat cancers. In March, Naya announced a “world‑class” board of directors, adding Ely Benaim, MD, Margarita Chavez, JD, Anne Lauvergeon, PhD, and Rahul Singhvi, PhD, MBA – a lineup that blends deep drug‑development, deal‑making, industrial, and company‑building experience. The new directors join a leadership platform anchored by CEO Daniel Teper, a veteran of oncology and regenerative medicine ventures under the broader NAYA Biosciences umbrella.
For family offices and top‑tier biotech VCs, this kind of governance reset functions as a bright, flashing due‑diligence beacon. Astatine‑211 has become one of the more closely watched isotopes in targeted radiopharmaceuticals, and Naya’s push to solidify its early leadership in the space – including U.S. supply chain partnerships and a bispecific antibody pipeline – has put the company squarely on the meeting agendas of healthcare‑focused family offices and specialist venture funds exploring their next wave of oncology exposure.
Over the past several weeks, Naya’s management and board have been in active discussions with these capital providers about the company’s next phase of development, from advancing lead candidates through key clinical milestones to scaling manufacturing and commercial infrastructure suitable for a new class of alpha therapies. For families already leaning into healthcare as a multigenerational theme, the pitch is straightforward: marry a differentiated radiopharmaceutical platform with a board that has lived through drug approvals, M&A cycles, and public‑market transitions, and you have a candidate not just for a single exit, but for a franchise.
AI Still Wears The Sector Crown
Healthcare’s April glow‑up didn’t happen in a vacuum. For much of the past year, AI has been the undisputed star of family office portfolios, topping CNBC’s Family Office 15 ranking by deal count and dominating JPMorgan’s survey of thematic priorities. Hillspire, the office for former Google CEO Eric Schmidt, led the 2025 deal‑makers list with a string of AI‑heavy bets, from voice technology to fusion energy, setting a blueprint for other wealthy families eager to align with the next computing wave.
Yet the latest data show that healthcare is increasingly sharing the spotlight. In CNBC’s reporting, AI, technology, and software collectively captured more than a third of family office transactions, with healthcare and biotech emerging as the next‑largest buckets. If last year’s playbook was “AI everywhere,” April’s version reads more like “AI everywhere – especially in your doctor’s office.”
Private Capital Steps In As Public Funding Steps Back
One reason healthcare is drawing more family‑office firepower is that federal research dollars aren’t exactly racing higher. An April budget proposal from the Trump administration calls for cuts to National Institutes of Health funding, raising questions about who will bankroll the next generation of drugs, devices, and diagnostics. Into that gap steps private wealth – patient, mission‑driven, and increasingly data‑informed.
This is not purely altruism, of course. Healthcare and biotech have long offered asymmetric upside when science, regulation, and market timing line up – a fact not lost on families whose fortunes were often built on earlier waves of disruption, from generics to vaccines. For them, backing platforms that can lower costs, improve outcomes, or tackle aging itself is both a business proposition and a way to future‑proof the family story.
What April Signals For The Rest Of 2026
The April rebound follows a choppy stretch. Family offices entered 2026 on a subdued note, with January and December deal volumes down sharply year‑over‑year as tariff concerns and geopolitical shocks kept risk appetite in check. February brought a surge in AI‑focused investments, and now April has delivered a clear rotation toward healthcare, suggesting that risk is back on – selectively.
If the pattern holds, the remainder of 2026 could see family offices leaning harder into themes that marry durable demand with technological leverage: AI‑assisted diagnostics, mental health platforms, women’s health, neurodegenerative disease – and alpha radiotherapies like those under development at Naya. That doesn’t mean every pitch deck with a molecule and a machine‑learning model gets a term sheet, but it does mean founders in those lanes will find a growing audience that thinks in generations, not quarters.
For investors watching from the public markets, the message is subtle but clear: when the world feels uncertain, the ultra‑wealthy are still willing to write big checks – they’re just writing them to companies trying to fix the human body, with platforms like Naya’s sitting squarely in that crosshairs.
The Sources
CNBC – “Family office deal-making rebounds in April with healthcare bets” https://www.cnbc.com/2026/05/07/family-office-dealmaking-april-healthcare-bets.htmlcnbc
Longbridge / syndicated CNBC piece – “Family office deal-making rebounds in April with healthcare bets” https://longbridge.com/en/news/285546281longbridge
CNBC – “Inside Wealth Family Office 15: Most active investment firms and themes” https://www.cnbc.com/2026/02/12/inside-wealth-family-office-15.htmlcnbc
CNBC – “Family office deals cooled off in December, but heirs still took risks” https://www.cnbc.com/2026/01/08/family-office-deals-bets-december.htmlcnbc
CNBC – “Where billionaires’ investment firms placed their bets in 2025” https://www.cnbc.com/2026/02/05/billionaire-investing-family-office.htmlcnbc
CNBC – “Family offices double down on AI investments as startup valuations reset” https://www.cnbc.com/2026/03/05/family-offices-ai-investments.htmlcnbc
NBC News – “Family offices ramp up dealmaking in June with bets on biotech” https://www.nbcnews.com/business/personal-finance/family-offices-ramp-deal-making-june-bets-biotech-rcna217299nbcnews
Dakota – “February 2026 Family Office Investments” https://www.dakota.com/reports-blog/february-2026-family-office-investmentsdakota
The FO Pro – “Deal Round-Up: Family Offices Make Moves in Health Care, Manufacturing and Public Markets” https://thefopro.com/deal-round-up-family-offices-make-moves-in-health-care-manufacturing-and-public-markets/thefopro
Future Family Office – “Family Office Dealmaking Rebounds With Big Healthcare Bets” https://futurefamilyoffice.net/news/family-office-dealmaking-rebounds-with-big-healthcare-bets/futurefamilyoffice
CNBC – “Another alliance of health care and AI signals why pharma stocks could be back” https://www.cnbc.com/2026/01/20/another-alliance-of-health-care-and-ai-signals-why-pharma-stocks-could-be-back.htmlcnbc
LinkedIn – Naya Therapeutics post on world-class board announcement https://www.linkedin.com/posts/naya-therapeutics_naya-therapeutics-announces-world-class-board-activity-7439683577744715776-lU_wlinkedin
LinkedIn – Daniel Teper post on Naya, astatine‑211 and new board members https://www.linkedin.com/posts/danielteper_astatine211-activity-7440011740693676032-ysOglinkedin
Yahoo / GlobeNewswire – “NAYA Biosciences Announces Nomination of New Board Members” https://finance.yahoo.com/news/naya-biosciences-announces-nomination-board-141500586.htmlfinance.yahoo
April’s consumer price index didn’t exactly crash the party, but it did show up with an extra guest: a touch more inflation than markets ordered. Year‑over‑year CPI rose about 3.8% in April, marginally topping economists’ expectations of roughly 3.7% and marking a jump from March’s 3.3% pace.
That puts inflation at its highest level in almost three years, powered less by consumers’ enthusiasm and more by the rising cost of energy and a few stubborn essentials that refuse to go on sale. Investors who started the year dreaming about multiple rate cuts are now revising those fantasies down to something closer to “maybe later.”
Gasoline Takes the Lead Role
If April’s inflation report were a movie, gasoline would be the star, the producer, and possibly the craft‑services budget. A sharp run‑up in gas prices— (we just paid $7/gallon last night in San Francisco) fueled by ongoing conflict with Iran and higher oil benchmarks—has filtered quickly into the CPI data. Since late February, pump prices have climbed dramatically, with gas up nearly 50% from the onset of the conflict and more than 28% year‑over‑year.
The mechanics are straightforward even if the receipts are painful: higher crude prices flow into gasoline, which in turn raises transportation and logistics costs, which then quietly inflate the price tags on everything from groceries to furniture. For most households, the most visible reminders live on the gas station marquee and in the meat aisle, where beef prices have jumped nearly 15% from a year earlier.
The Fed’s Patience Gets Another Test
For the Federal Reserve, April’s data falls into the category of “inconvenient but not catastrophic.” Inflation is clearly above the central bank’s 2% target, and the reacceleration from March’s 3.3% pace to 3.8% will not encourage officials to reach for the rate‑cut lever anytime soon.
Coming into the year, markets were pricing in an aggressive path of easing; by now, those expectations have been trimmed as persistently firm inflation and higher energy prices complicate the outlook. Policymakers can still argue that some of the pressure reflects temporary pass‑through from oil and geopolitical shocks, but each hotter‑than‑hoped monthly reading nudges them toward a longer “wait and see” stance.
Households Feel It at the Everyday Level
The CPI may be an index, but it lands in very human places: the grocery cart, the commute, the utility bill. Food prices are running a bit over 3% higher than a year earlier, adding a steady headwind to household budgets even as some goods categories have cooled from the post‑pandemic surge.
Housing and energy continue to do their part as well, with shelter costs and fuel contributing a meaningful share of the monthly gain. For many families, the mental CPI boils down to two lines: the cost of filling the tank and the price of a pound of beef—both of which have been moving in the wrong direction. The State Street Energy Select Sector SPDR ETF, an ETF that focuses on large-cap energy stocks like ExxonMobil (XOM, $127.36, +1.37%), Chevron, and ConocoPhillips, is up 28.27% YTD.
Markets Juggle Higher Oil and Higher Hopes
Equity markets took the April data in stride but not in silence. Oil prices and Treasury yields have been drifting higher, reflecting both geopolitical risk and the sense that “higher for longer” may apply to rates as well as energy. Yet risk appetite has hardly evaporated; chip stocks and other growth names have continued to push major indexes toward or into fresh records, suggesting investors still see enough earnings power to look through inflation bumps—for now.
The picture is nuanced: hotter CPI and pricier oil lean against early rate‑cut hopes, but strong corporate profits and resilient demand keep the floor from falling out under equities. In classic Wall Street fashion, the market seems willing to live with 3‑something inflation so long as earnings stay 10‑something and GDP avoids anything starting with a zero.
What It Means for the Months Ahead
April’s CPI report doesn’t rewrite the economic narrative, but it does edit a few key lines. With inflation ‘re‑accelerating’ and energy acting as an unwelcome supporting actor, the bar for near‑term Fed easing has moved higher, and rate‑sensitive sectors will trade accordingly.
For households, the near‑term prescription is familiar: watch gas and grocery bills, brace for elevated summer travel costs, and hope the current oil‑driven pressures prove more spike than trend. For investors, the story is a bit more nuanced—a world where inflation isn’t spiraling, but isn’t quite ready to fade into the background either.
Wise Group (WSE), the London-born money-transfer specialist, rang in its first day on Nasdaq with the kind of quiet confidence usually reserved for seasoned Wall Street incumbents rather than European fintech “tourists.” By shifting its primary listing from the London Stock Exchange to New York—while keeping London as a secondary home—Wise is effectively declaring that its future, and perhaps much of fintech’s, will be written in U.S. dollars as much as in code.
The move is framed less as an escape from London and more as a gravitational pull toward the world’s deepest capital market, where liquidity, analyst coverage, and institutional ownership can turn a solid niche business into a global payments franchise. Wise’s leadership is signaling that if you want to reshape how money moves across borders at scale, you do it on the exchange where capital itself crosses borders every millisecond.
From London Listing to Nasdaq Narrative
Wise first listed in London in 2021, a high-profile direct listing that helped bolster the City’s tech credentials after Brexit. But as the company’s cross‑border volumes swelled and U.S. customer numbers climbed, so too did the logic of aligning its corporate address with its growth engine.
By 2026, management concluded that New York wasn’t just another listing venue; it was the natural home for a company aiming to be the default rail for global money movement, especially for U.S. consumers and businesses who are still overpaying quietly for international transfers via legacy banks. Nasdaq brings extended trading hours, deeper liquidity, and a broader peer group of high‑growth fintech and payments names—a narrative Wise can now slip into as easily as it routes a payment from Dallas to Delhi.
The U.S. Fintech Prize: A Trillion‑Dollar Traffic Jam
Behind the listing lies a brutally simple thesis: the U.S. is the biggest under-modernized prize in global payments. Americans and U.S.-based businesses move enormous sums across borders each year, but much of that flow still travels on rails laid down when “cross-border” meant paper forms and long lunches, not APIs and real-time confirmation.
Industry estimates put global cross‑border flows in the tens of trillions annually, with U.S. outbound remittances and B2B payments alone representing a multi‑trillion-dollar opportunity. Despite a proliferation of digital wallets, new rails, and blockchain experiments, roughly 80% of outbound U.S. cross‑border payments still lean on SWIFT and incumbent infrastructure. That gap between what’s possible and what’s practiced is where Wise sees room to insert itself—and to siphon away the billions in hidden fees Americans are projected to lose on cross‑border transactions this year.
For investors, the U.S. market isn’t just large; it’s sticky. Once a business or household bakes a cross‑border provider into payroll, supplier payments, or tuition and mortgage flows, the switching costs become measured not in basis points but in operational headaches—an advantage for any fintech that can get in early and stay reliable.
Scaling the Rails: Bank Charter Dreams and Fed Ambitions
The Nasdaq move is only one pillar of Wise’s U.S. strategy; the company is simultaneously rewiring its regulatory and infrastructure footprint to plug deeper into the American financial system. Wise has applied for a national trust bank charter in the U.S., a move that would allow it to operate more like a regulated bank for its core activities, while still presenting itself to consumers as a nimble fintech rather than a marble‑lobby institution.
That charter is a prelude to a more potent prize: a Federal Reserve master account. With direct access to the Fed’s payment systems, Wise could move U.S. dollar flows without always leaning on partner banks, potentially cutting costs, reducing settlement risk, and speeding up transfers for customers. This is part of a broader trend of fintechs trying to bypass traditional correspondent chains and plug directly into central bank plumbing, turning what used to be a bank club privilege into something more competitive.
If approved, this twin-track—capital markets scale via Nasdaq and infrastructure depth via the Fed—positions Wise less as a consumer app and more as a cross‑border utility: a specialized, globally connected money pipeline built for modern commerce.
The Numbers Behind the Narrative
Wise arrives on Nasdaq with more than a story; it arrives with velocity. The company recently reported cross‑border volumes of roughly $243 billion, up 31% year‑on‑year, indicating that customers are not just signing up but meaningfully shifting their money habits. Customer holdings reached about $39 billion, a 40% increase, while transaction revenue climbed to around $1.9 billion, up 22%, and net revenue to $2.5 billion, up 19%.
Those figures reflect a business that has moved beyond the “cheap transfer” stereotype into a multi‑currency account and infrastructure platform, serving both consumers and enterprises. For U.S. investors accustomed to tracking gross payment volumes and take rates across the broader fintech universe, Wise’s metrics slide neatly into existing playbooks—just with a cross‑border tilt and a European accent.
London’s Loss—or a Fintech Coming of Age?
Wise’s shift is widely interpreted as another data point in London’s struggle to retain high‑growth tech listings in the face of richer valuations and deeper liquidity in New York. Yet the company’s decision to maintain a secondary London listing offers a more nuanced reality: global fintech champions will increasingly be dual citizens of capital markets, anchored where their customers and cost of capital align best.
For London, Wise’s evolution may serve as a wake‑up call to further sharpen listing rules and investor engagement for growth companies. For Nasdaq, it is a validation that the exchange remains the favored arena where global fintechs go from regional curiosities to systemically relevant networks. And for Wise, it’s an opportunity to tell its growth story each quarter to a U.S. audience that understands the compounding power of transaction‑based, software‑enabled business models.
A Fintech in the Right Place at the Right Time
The U.S. payments landscape is entering a period of intense experimentation and fragmentation, with card rails, RTP networks, digital wallets, and stablecoin initiatives all competing to define the future of cross‑border money movement. In this environment, infrastructure players that can offer predictable, low‑cost, and transparent rails across currencies are positioned as the steady adults in a room full of promising-but-volatile newcomers.
Wise’s bet is that as U.S. consumers and businesses get used to instant domestic transfers, they will increasingly demand the same experience when money crosses borders—and they will look for providers that already operate at global scale. By anchoring its listing, regulatory ambitions, and operational build‑out in the U.S., Wise is attempting to be that infrastructure player, turning what used to be a painful line item on a bank statement into a predictable, software‑driven utility.
If the company executes, its Nasdaq symbol, WSE, may come to represent more than just one stock; it could become shorthand for a broader shift in how and where the world’s money moves—and how much of that value accrues to the firms that build the rails rather than just ride them.
U.S. News & World Report – “Wise Set to Make Nasdaq Debut as Company Completes Shift From London” (syndicated Reuters coverage)money.usnews U.S. News: Wise Nasdaq debut
US stocks finished modestly higher across the board on Monday, with the Dow grinding up, the S&P 500 and Nasdaq notching fresh record closes, and energy leading as oil jumped +3.09% to $98.37/bbl on renewed Middle East tensions and “CPI Eve” nerves.
Today’s Tape: Edges Up, Not Blows Out
The S&P 500 pushed to a new all‑time high above 7,400, with gains of roughly a quarter to a third of a percent into the close.
The Nasdaq also eked out another record, helped by ongoing AI enthusiasm and a fresh leg in select chip names.
The Dow started in the red but recovered to finish slightly positive, reflecting a “buy-the-dip” bias despite headline risk.
The small caps on the Russell 2000 also rose .33% to 2,870.64.
Trading had all the hallmarks of an index‑level melt‑up: narrow gains at the top, leadership in energy and AI, and plenty of skepticism underneath the surface.
Macro: Between Jobs Strength and CPI Jitters
The macro backdrop coming into today was shaped by Friday’s stronger‑than‑expected April payrolls report, which showed 115,000 new jobs versus ~55,000 expected and helped power last week’s breakout to new highs. The unemployment rate held around the mid‑4% area, keeping the “slow‑but‑still‑growing” narrative intact.
At the same time, earlier CPI data showed inflation re‑accelerating on the back of energy, with March headline CPI up 3.3% year‑over‑year and gasoline prices jumping over 20% in a single month, something the Fed has been watching closely. That makes tomorrow’s April CPI report the single dominant macro catalyst this week, with consensus looking for roughly 0.6% month‑over‑month headline and 0.3% core, and markets keen to see whether energy costs start bleeding more visibly into core categories.
Fed‑speak and rate expectations remain the quiet driver in the background: solid growth plus sticky inflation argues for patience, and the bar for near‑term cuts stays high, even as equities grind higher.
Geopolitics, Oil, and the Energy Bid
The “hard” macro data shared the stage today with a renewed geopolitical shock premium. Over the weekend, President Donald Trump rejected Iran’s latest peace proposal on the conflict that has effectively choked off traffic through the Strait of Hormuz. In a social‑media post he branded Iran’s response “TOTALLY UNACCEPTABLE,” signaling that negotiations are stalled and the naval standoff will likely persist.
That rhetoric helped push Brent crude up roughly 3%‑plus toward and above the 100‑dollar mark, with West Texas Intermediate climbing into the high‑90s as traders priced in prolonged constraints on crude and LNG flows. The International Energy Agency has already described this as the largest supply shock in modern history, and today’s move reinforced that oil remains a primary inflation transmission channel.
Energy stocks responded in kind, leading the S&P 500 as investors rotated toward producers, refiners, and other beneficiaries of elevated crude, even as high pump prices weigh on consumer sentiment.
AI and Semis: Still the Market’s Security Blanket
Despite the geopolitical noise, enthusiasm around AI and the chip complex continues to be the market’s dominant equity theme. Today’s tape again saw “AI infrastructure” at the center of flows—semiconductor names and key AI hardware suppliers stayed in demand, with investors treating them as secular growth stories that can outrun macro bumps.
This comes after a six‑week winning streak for both the S&P 500 and the Nasdaq, propelled in no small part by AI‑linked earnings and guidance. With more tests of the theme on deck—earnings this week from companies like Cisco (CSCO, $98.72, +2.23%), Alibaba, and Applied Materials (AMAT, $435.36, +6.03%)—positioning around AI remains a core driver of breadth and sentiment.
For now, traders appear comfortable paying up for secular growth in chips and cloud, even as they hedge cyclical and rate‑sensitive areas into tomorrow’s CPI.
The Week Ahead: CPI “Event Risk” Front and Center
Markets head into Tuesday in an uneasy equilibrium: record equity prices, a firm energy bid, and a Fed that is in no rush to pivot. The calendar gets busy quickly:
Tuesday: April CPI, the marquee event, with headline and core readings likely to reset rate‑cut odds for the June and September FOMC meetings.
Wednesday: Producer Price Index, giving a read on pipeline inflation pressures.
Thursday: Retail sales, key for assessing how much high gas and food prices are biting the consumer.
Friday: Preliminary University of Michigan sentiment, which has already slumped toward crisis‑era lows despite equity records.
The overarching setup: risk assets are priced for a “soft‑ish landing” with still‑resilient growth, while energy‑driven inflation and geopolitical risk keep the macro ceiling low. For now, the market is choosing to focus on AI earnings and momentum, but tomorrow’s CPI print will test just how much inflation heat investors are willing to look through.
VP Watchlist Updates
Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.
Amwell® (NYSE: AMWL, $8.15, +2.26%)
Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology- enabled healthcare platform, announced (May 5) financial results for the first quarter ended Mar. 31, 2026. “Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”
FMC Corporation (NYSE: FMC, $13.11)
FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.
Eupraxia Pharmaceuticals (EPRX, $7.42)
Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.
Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.
Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, saw (May 1) CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.
The InterGroup Corporation (INTG, $36.88, +.11%)
InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.
Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO, +11.20%)
NVIDIA will host a conference call on Wednesday, May 20, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the first quarter of fiscal year 2027, which ended April 26, 2026. The call will be webcast live (in listen-only mode) oninvestor.nvidia.com.
McDonald’s (MCD, $274.60)
Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .
Tesla (TSLA, $445, +3.89%)
Tesla’s latest reveal reads a bit like a family group chat gone public—over $500 million in revenue tied to Elon Musk’s own empire, because apparently vertical integration now includes your boss’s other companies. Meanwhile, the solar business is having a cloudy moment, robotics competition is heating up, and just to keep things interesting, Tesla snagged a jaw-dropping 370 Semi order. Oh, and in case that wasn’t enough, there’s talk of a casual $119 billion chip manufacturing push—because why not add semiconductors to the to-do list?
Serina Therapeutics (NYSE: SER, $1.60)
Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.
What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.
Intel (INTC, $129.44, +3.64%)
Intel’s latest rally is more than just another chip stock pop; it’s the market’s way of voting “yes” on a reshuffled AI and manufacturing order in which Intel (INTC), Apple (AAPL), and Nvidia (NVDA) are quietly rehearsing for a new ensemble performance. Beneath the headlines about exploratory talks and record highs is a deeper story about supply chains, national strategy, and a former laggard that suddenly finds itself back on center stage.
Icarus Robotics is tackling one of the commercial space industry’s most expensive inefficiencies: astronaut labor costs $130,000 per hour, yet highly-trained scientists spend significant time unpacking cargo and performing routine maintenance. The New York-based startup, founded in 2024 by 22-year-old Ethan Barajas and 25-year-old Jamie Palmer, is building AI-powered autonomous robots to handle orbital grunt work so astronauts can focus on groundbreaking microgravity research.
With a $6.1 million seed round raised in September 2025 and a high-stakes International Space Station mission scheduled for early 2027, Icarus is positioning itself as the robotic labor force for the emerging commercial space economy.
The Founders’ Unconventional Journey
Barajas and Palmer bring remarkably diverse backgrounds to space robotics. Barajas began interning at NASA at just 17 years old, worked on lunar rovers, and dropped out of Caltech after three years to launch Icarus. Palmer, originally from Tipperary, Ireland, earned his Master’s in Robotics from Columbia University on a full scholarship, researching intelligent dexterous manipulation in the ROAM (Robotic Manipulation and Mobility) Lab. Before co-founding Icarus, Palmer served as a test engineer with the Mercedes-AMG Petronas Formula One team, bringing high-performance engineering expertise to the venture.
The duo was recognized on Forbes’ 30 Under 30 Science list for 2026, with their work featured as a headline callout for the category.
The Brooklyn Navy Yard Testing Ground
Icarus Robotics operates from New York City, where the team has established its headquarters and testing facilities. The founders are developing “Joy,” their free-flying robotic platform designed to operate autonomously inside crewed space stations using embodied AI—robots that learn from human demonstrations and scale across various labor tasks. The company represents one of the first ventures bringing embodied AI technology to space operations, creating human-controlled systems that can handle cargo management, maintenance, and eventually orbital construction.
Mission “JoyRide 1”: Testing Autonomous Capabilities in 2027
Icarus has partnered with Voyager Technologies (NASDAQ: VOYG) for mission management support on its inaugural ISS demonstration, dubbed “JoyRide 1”. Scheduled for early 2027, this yearlong test mission will validate Joy’s autonomous navigation, maneuverability, and operational performance in the live space station environment. The initial flight will test nominal functions including motion primitives such as free-flying, single-arm manipulation, and bimanual operations, alongside sensing modalities like IMU, visual-inertial systems, depth perception, and advanced perception capabilities.
Voyager Technologies will handle payload integration, safety certification, launch coordination, and on-orbit operations for the mission. The demonstration aims to prove advanced robotic capabilities including dexterous manipulation and autonomous tool use in low-Earth orbit.
The Drive Behind Icarus: “So Others May Live”
The company’s mission extends beyond pure efficiency gains. By delegating tedious tasks to robots, Icarus aims to free astronauts “to focus on the groundbreaking discoveries that only astronauts can do,” according to Barajas. As commercial space stations proliferate and the orbital economy expands, the labor bottleneck in space becomes increasingly acute. Icarus is positioning its robotic workforce as essential infrastructure for trillion-dollar orbital economies, with plans to expand from commercial stations to EVA (extravehicular activity) capabilities and eventual Moon and Mars adaptations.
The startup’s roadmap includes deploying multi-station fleets following the 2027 ISS prototype, capitalizing on embodied AI trends and accelerating space commercialization to potentially become the backbone of orbital labor.
DEEP, a quietly ambitious ocean engineering company with the slogan “Make Humans Aquatic,” is turning a flooded British quarry into something between a deep‑sea university campus and a very serious playground for saturation divers. At its new Chepstow facility, a 50‑acre former limestone pit is being repurposed as a controlled underwater testbed where people will learn to live and work beneath the surface for weeks at a time rather than a single tank of air.
A Quarry Becomes a Quiet Revolution
Once known to UK divers as the National Diving and Activity Centre, the quarry at Tidenham near Chepstow was already famous for depths reaching roughly 80 meters and clear, cold water that drew technical and military divers. Now, under DEEP’s ownership, the 600‑meter‑long lake is being reimagined as “DEEP Campus,” a secure freshwater facility designed for advanced training, research and equipment testing, complete with shore‑based engineering support, accommodation and year‑round access.
On paper, the site reads like a classic repurposing story: industrial extraction gives way to intellectual exploration, as rock hauling is replaced by data gathering. In practice, it is a sizable infrastructure bet—DEEP and local officials have flagged a planned investment of around £100 million in turning the quarry into a regional hub for underwater technology, with jobs expected in engineering, R&D, logistics and hospitality.
Making Humans Aquatic (Without the Gills)
DEEP’s pitch is disarmingly simple: if you want to understand the ocean, you should spend more than a coffee break in it. Traditional diving limits researchers to a handful of underwater hours per day, with resurfacing and decompression consuming valuable time and adding risk; DEEP’s subsea habitats aim to invert that ratio by letting people stay down for days or even weeks at a stretch.
The company’s CEO has described the habitats as “time machines,” a nod to the way saturation living stretches what can be accomplished on a mission. By maintaining divers at pressure, the system cuts out the constant yo‑yoing to the surface and opens the door to continuous operations—more measurements taken, more samples collected and more problems solved before the team has to pack up and go topside.
Inside DEEP Campus: A Training Ground Below the Surface
At the heart of DEEP Campus is the controlled body of freshwater, bordered by a private 50‑acre perimeter that keeps currents, shipping lanes and curious paddleboarders out of the equation. The lake’s depth profile—down to about 80 meters, with long, clear stretches—makes it unusually well‑suited to saturation diving drills, closed‑bell operations and the careful choreography of placing and retrieving subsea hardware.
Along the shore, DEEP is building out a suite of support assets more reminiscent of an aerospace test range than a weekend dive center: engineering workshops, test rigs, accommodation blocks and shore‑based control rooms that can monitor dives, habitats and submersibles in real time. The company has flagged plans for amenities ranging from a submarine garage to visitor facilities and even a tunnel link to nearby hotel accommodation—because if you are going to ask people to live like aquatic astronauts, you may as well offer them a decent coffee when they re‑pressurize.
Vanguard, Sentinel and the Modular Ocean Frontier
The Chepstow site is not just a training pool; it is the proving ground for DEEP’s subsea habitat line‑up, a modular system built around two core platforms called Vanguard and Sentinel. Vanguard is the smaller pilot habitat—roughly 12 meters long and 7.5 meters wide—designed for missions of up to a week with three occupants and aimed at tasks such as rapid‑response search operations or short, intensive research campaigns.
Sentinel is the big swing: an expandable network of interconnected modules intended to support teams of six to 50 people at depths of up to about 200 meters for up to a month. Built from standardized, 3D‑manufactured components that can be configured into different layouts, the system is meant to be recoverable, re‑deployable and scalable, more like a subsea space station kit than a single fixed‑location lab. DEEP and its partners have talked openly about 2027 as the target date for a permanent human presence underwater, with the Chepstow campus serving as the dry run before habitats are dispatched to sites around the world.
Saturation Diving: Training for Aquatic Astronauts
The backbone of this vision is saturation diving, a technique perfected in the offshore energy sector and now poised for a broader research role. In a saturation regime, divers live in a pressurized environment—on the surface in a chamber, or underwater in a habitat—for extended periods, traveling to and from their worksite in a closed diving bell instead of constantly ascending and descending through the water column.
DEEP Campus is being promoted as home to the only closed‑bell diving system of its kind in the Northern Hemisphere, along with an extended menu of training courses spanning habitat diving, professional scuba, rebreather techniques, surface‑supplied systems and diver medic qualifications. For divers and engineers, the combination of depth, infrastructure and advanced kit effectively turns the quarry into a graduate school for extreme environments, the sort of place where you might bump into a future offshore wind engineer on one dive and a future Mars‑analogue astronaut on the next.
Why Tech and Investors Are Paying Attention
While the idea of living underwater evokes science fiction, the economics are rooted firmly in this world. As offshore wind arrays push into deeper waters, subsea data cables multiply and coastal resilience becomes a global priority, the demand for robust underwater infrastructure—and people trained to install, maintain and inspect it—is rising.
A modular habitat system that can be deployed near new fields, cable routes or research sites offers a way to cut time, cost and risk across industries from energy to telecommunications to marine biotech. Meanwhile, the research upside is substantial: with only one permanent underwater lab in operation globally today, the addition of a network of habitats could accelerate work on everything from coral resilience and carbon cycling to the engineering lessons needed for future space habitats.
Chepstow’s Deep Future
For Chepstow and the surrounding region, DEEP’s campus carries the promise of a new industrial identity built around engineering talent, high‑spec manufacturing and niche tourism, rather than quarrying and weekend thrill‑seeking. If timelines hold, the site is expected to ramp up activity through the middle of the decade and feed into the company’s broader aim of seeding underwater stations worldwide by 2027.
If it succeeds, the quiet lake on the Welsh border may become a footnote in a much larger story: the moment humans stopped treating the ocean as a destination and started treating it as an address. For now, Chepstow’s hidden campus is where that future is being pressure‑tested—one saturation dive, one modular habitat and one very patient quarry at a time.
DEEP – Main site: overview of DEEP’s ocean engineering and modular habitat concept. https://www.deep.comdeep
DEEP Campus – “Underwater Training & Testing” (details on the Chepstow campus: size, depth, facilities, and saturation diving training). https://www.deep.com/locations/campusdeep
DEEP Institute – training and subsea testing facility information (fresh‑water site, depth, length, and on‑site engineering support). https://www.deepinstitute.comdeepinstitute
Chandler, AZ’s Everspin’s (MRAM) new $40 million defense pact reads less like a routine semiconductor contract and more like a carefully scripted act in Washington’s ongoing bid to onshore critical tech—with an Arizona memory specialist unexpectedly cast in a leading role.
Everspin’s $40 Million Moment in the Defense Spotlight
In late April, Chandler, Arizona–based Everspin Technologies announced a $40 million agreement tied to military and aerospace applications for its Toggle MRAM process technology and engineering services, positioning the company squarely inside the U.S. Defense Industrial Base spotlight. The deal runs roughly two and a half years and is structured as a subcontract under an existing U.S. government prime contract, linking Everspin to a broader federal microelectronics R&D push rather than a one-off parts order.
For a firm whose ticker is literally MRAM, landing a multi‑year defense program is more than poetic branding; it is a validation that its niche non‑volatile memory has moved from industry curiosity to strategic asset. In a sector where contracts often arrive with asterisks, caveats, and acronyms, a clearly defined, funded agreement of this size offers something rare in semis: line‑of‑sight revenue and a clearer narrative for investors.
Why the Pentagon Cares About Tiny Bits
The new agreement taps Everspin to supply cutting‑edge Toggle MRAM process technology and specialized engineering services to defense customers whose systems operate where failure is not a rounding error—it is a mission. MRAM’s combination of non‑volatility, high endurance, and radiation tolerance has already earned it a role in satellites, aerospace systems, and other environments where cosmic rays care little about quarterly guidance.
Unlike traditional memory, Everspin’s radiation‑hardened MRAM has been shown to maintain data integrity at total ionizing doses above 1 Mrad, a threshold that would make most conventional chips forget their own spec sheets. That resilience—coupled with endurance measured in trillions of read/write cycles and long‑term data retention at elevated temperatures—makes the technology particularly attractive for emerging edge‑computing defense workloads that need both speed and staying power.
Onshoring the Memory Supply Chain
Beyond the headline number, this deal is part of a broader national effort to secure critical semiconductor manufacturing onshore, a theme that has moved from policy panels to procurement orders. Everspin has emphasized that the program expands its U.S.‑based Toggle MRAM capabilities and directly supports government initiatives aimed at bolstering the domestic Defense Industrial Base.
A key enabling piece is Everspin’s recently announced foundry services agreement with Microchip Technology, (MCHP) which gives the company a second, fully U.S.‑based manufacturing source at a fab in Oregon. That long‑term strategic deal—which includes support for ITAR‑compliant wafer processing—effectively upgrades Everspin from an interesting supplier to a structurally important node in the defense memory supply chain. For policymakers worried about foreign chokepoints in advanced chips, having an onshore MRAM specialist capable of scaling production is the semiconductor equivalent of finding a reliable plumber in a town obsessed with luxury faucets.
From Niche Player to Narrative Stock
The $40 million contract arrives alongside solid operating momentum: Everspin recently reported first‑quarter 2026 revenue of about $14.9 million and non‑GAAP net income near $2.6 million, underscoring that this is not a pre‑revenue science project but a profitable, if still small‑cap, enterprise. Market commentators have noted that the agreement, which equals several quarters’ worth of current revenue, could meaningfully reshape how investors frame the company’s risk‑reward profile.
Early trading reactions have reflected that shifting narrative, with the stock rallying sharply +50% on Monday, May 22 as the market seems to be re‑rating Everspin from a cyclical memory micro‑cap to a defense‑levered, strategic‑tech story. While the contract does not erase the usual semiconductor risks—demand cycles, pricing pressure, and technology transitions—it does inject multi‑year visibility and a government‑backed growth vector into the model. For a company making bits, this is the kind of “bit of news” that can change capital allocation discussions from survival to strategy.
MRAM at the Edge of War and Space
The defense agreement arrives as MRAM gains traction in secure, power‑efficient computing at the edge, where systems may need to process data locally, survive harsh environments, and boot instantly without waiting for a distant data center to wake up. Everspin and its partners already have significant MRAM deployments in space and other radiation‑prone settings, and the company positions itself as the only MRAM provider with U.S. manufacturing across this class of application.
That footprint dovetails neatly with the Pentagon’s interest in resilient electronics for satellites, drones, and next‑generation communications systems, all of which benefit from memory that can shrug off single‑event upsets and keep critical data intact. In that sense, the $40 million pact is less an isolated win and more a milestone in MRAM’s steady promotion from promising technology to default choice in some of the most demanding mission profiles on (and above) the planet.
A Small Cap Playing a Big Strategic Game
For Everspin, the strategic value of this agreement arguably rivals the dollar value. The contract embeds the company deep inside an existing prime‑contractor program, broadens its relationships across the Defense Industrial Base, and signals government confidence in both its technology and its manufacturing roadmap. It also creates a foundation from which follow‑on programs, derivative designs, and expanded capacity commitments could emerge as defense and aerospace platforms adopt MRAM more broadly.
In an era when and “supply‑chain resilience” routinely share a sentence with “budget appropriations,” having a U.S.‑based, radiation‑tolerant memory specialist under contract is an asset that extends beyond quarterly EPS math. For investors, the takeaway is straightforward: in Chandler, the bits are small, the wafers are thin, and the contract line items are dense—but the emerging role in defense technology looks decidedly large.
The trillion-dollar club just welcomed its 13th member, and spoiler alert: it’s not another social media platform promising to revolutionize how we share brunch photos. Samsung Electronics officially crossed the $1 trillion market capitalization threshold this week, cementing a remarkable transformation in what defines elite corporate status in 2026. The South Korean tech titan joins Nvidia (NVDA), TSMC (TSM), and Broadcom (AVGO) in representing a new wave of market royalty—one that’s decidedly more tangible, more physical, and more obsessed with actual silicon than its predecessors.
The Original Gangsters vs. The Infrastructure Insurgents
The first modern trillion-dollar club featured the usual suspects: Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL), Amazon (AMZN), and Meta Platforms (META)—companies built on smartphones, cloud computing, search engines, social media, and e-commerce dominance. Tesla (TSLA) rode the electric vehicle momentum into temporary membership, while Berkshire Hathaway (BRK-B) became the first US non-tech company to join in 2024. Walmart (WMT) achieved the distinction of first retailer to enter the club in 2026, and Eli Lilly (LLY) briefly flirted with membership thanks to insatiable GLP-1 demand. Even commodity giants Saudi Aramco (2222.SR) and PetroChina (0857.HK) enjoyed their trillion-dollar moments.
But this newer wave? It’s built on chips, memory modules, and the unsexy infrastructure that actually makes artificial intelligence compute.
The AI Infrastructure Gold Rush
Nvidia blazed the trail in May 2023, becoming the first pure-play AI infrastructure company to hit $1 trillion as the artificial intelligence compute trade detonated. The company didn’t stop there—it subsequently became the first to reach $4 trillion in July 2025 and $5 trillion in October 2025, with CEO Jensen Huang recently announcing $500 billion in AI chip orders. TSMC followed in 2024 as investors finally appreciated the world’s most important advanced-chip manufacturer, reaching a valuation of $1.28 trillion. Broadcom joined later that year, propelled by surging demand for custom AI chips and networking solutions, climbing to $1.82 trillion.
The pattern is unmistakable: AI is rewarding the bottlenecks. Tech giants Amazon (AMZN), Alphabet (GOOGL), Microsoft (MSFT), and Meta Platforms (META) plan to spend nearly $700 billion on AI infrastructure ramp-up in 2026 alone. Microsoft disclosed record capital expenditures approaching $35 billion for its fiscal first quarter, with expectations for further investment increases. When you’re building conventional 1-gigawatt AI data centers that require over $60 billion in investment—with roughly half allocated to hardware—someone’s making serious money on picks and shovels.
The Valuation Premium for Physical Computing
The semiconductor sector’s market value-to-capital expenditure ratio hit 75.1, the highest across all global sectors, signaling that investors anticipate substantial returns from AI-related investments by chip manufacturers. While Apple and Microsoft each achieved $4 trillion valuations by late October 2025, it’s the hardware manufacturers capturing the market’s imagination with triple-digit growth rates. Nvidia shares jumped over 170% in 2024, generating more than $130 billion in revenue during fiscal 2025. Broadcom surged 17% in a single month, TSMC added 15%, and Alphabet climbed 13%—all riding the AI infrastructure wave.
Meanwhile, Bank of America projects the AI data center systems market potential will exceed $1.5 trillion by 2030, with a compound annual growth rate of 38%, and AI accelerators alone representing a potential $900 billion opportunity. The firm anticipates global semiconductor sales will increase 30% year-over-year, enabling the industry to surpass $1 trillion in annual sales by 2026.
The Bottleneck Billionaires
At the very top of the market, the trillion-dollar club’s newest members prove a fundamental truth: in the AI boom, the infrastructure providers are capturing valuations that rival—and sometimes exceed—the platforms they enable. Samsung’s entrance alongside Nvidia, TSMC, and Broadcom represents not just four companies crossing an arbitrary threshold, but a wholesale revaluation of what matters in technology investing. Turns out that in 2026, manufacturing the chips, memory, and networking gear that power AI is just as lucrative—if not more so—than dreaming up clever applications to run on them.
The hardware makeover of market royalty is complete, and Wall Street couldn’t be happier about it.
The Sources
[1] The $1 trillion club’s new members are powering the AI boom https://finance.yahoo.com/markets/article/the-1-trillion-clubs-new-members-are-powering-the-ai-boom-chart-of-the-day-104234629.html [2] The $1 trillion club’s new members are powering the AI boom https://www.aol.com/articles/1-trillion-clubs-members-powering-104234000.html [3] List of Trillion-Dollar Companies 2026 – Admiral Markets https://admiralmarkets.com/education/articles/shares/trillion-dollar-companies [4] AI boom drives trillion-dollar tech valuations and record … https://finance.yahoo.com/news/ai-boom-drives-trillion-dollar-140839736.html [5] Nvidia hits $5 trillion valuation as AI boom powers meteoric … https://www.reuters.com/business/nvidia-poised-record-5-trillion-market-valuation-2025-10-29/ [6] Trillion-Dollar Companies: 10 Most Valuable Mega-Cap … https://www.bankrate.com/investing/trillion-dollar-companies/ [7] These 6 stocks will lead the $1 trillion chip surge in 2026 … https://finance.yahoo.com/news/these-6-stocks-will-lead-the-1-trillion-chip-surge-in-2026-bofa-says-130008431.html [8] Global markets: AI and chip boom fuel expansion of trillion-dollar club https://www.tradingview.com/news/moneycontrol:1a489cf37094b:0-global-markets-ai-and-chip-boom-fuel-expansion-of-trillion-dollar-club/ [9] The $1 trillion club’s new members are powering the AI boom https://x.com/YahooFinance/status/2053431360384127386 [10] Lucky number 13. There’s a new member of the $1 trillion … https://www.instagram.com/p/DYDhHmqkWE8/ [11] Trillion-Dollar Companies: What are They & Which is Next? https://www.cmcmarkets.com/en-gb/shares/trillion-dollar-companies [12] Anthropic Has Surged to a Trillion-Dollar Valuation on … https://www.businessinsider.com/anthropic-trillion-dollar-valuation-on-secondary-markets-2026 [13] Lucky number 13. There’s a new member of the $1 trillion … https://www.facebook.com/MorningBrew/posts/lucky-number-13theres-a-new-member-of-the-1-trillion-club-this-week-as-south-kor/1392068929623021/ [14] Trillion Dollar Companies 2026 | Mega Cap Stocks https://www.marketbeat.com/types-of-stock/trillion-dollar-companies/ [15] Meet The 45 AI Newcomers To Forbes’ 2026 Billionaires List https://www.forbes.com/sites/phoebeliu/2026/03/10/meet-the-45-ai-newcomers-to-forbes-2026-billionaires-list/
